Start With the Meaning
A hormone treatment described as natural, personalized, or bioidentical can sound reassuring, especially when menopause symptoms affect daily life. But those words alone do not show that a product is safer or more effective. Mayo Clinic’s guidance explains that bioidentical refers to a hormone’s chemical structure, not its safety or regulatory status.
That distinction matters: FDA-approved products can contain bioidentical hormones, while compounded products are custom-prepared by pharmacies and are not reviewed by the FDA for safety and effectiveness in the same way. The Menopause Society notes that approved products are available in different doses, so bioidentical does not automatically mean compounded.
This guide separates the terms and considers what each may mean for treatment choices. A clinician can help weigh symptom relief, medical history, preferences, and the evidence for a proposed therapy. At harmony.care, women’s health care takes an integrative approach, making individualized discussion part of considering options rather than assuming one formulation suits everyone.
What Menopausal Hormone Therapy Can Treat
Menopausal hormone therapy (MHT), also called hormone replacement therapy, uses estrogen to ease symptoms linked to changing or declining hormone levels during perimenopause and menopause. The treatment plan depends on which symptoms are most disruptive and a person’s health history.
Systemic therapy, delivered through options such as pills, patches, gels, or sprays, circulates through the body and can relieve bothersome hot flashes and night sweats. Low-dose vaginal estrogen works locally to ease vaginal dryness and discomfort, and may also help with some urinary symptoms. These approaches serve different needs, so discussing symptom priorities with a clinician can help guide the choice. ACOG’s overview of hormone therapy describes these treatment options.
For people with a uterus, systemic estrogen is generally paired with a progestogen to protect the uterine lining. Systemic estrogen may also help prevent bone loss in appropriate patients, but hormone therapy is not prescribed solely to prevent heart disease or dementia. At harmony.care, menopause care is framed around integrative, personalized assessment, while treatment decisions remain grounded in an individual’s symptoms, medical history, and discussion with a qualified healthcare professional.
Bioidentical Does Not Mean Compounded
Bioidentical hormones have the same chemical and molecular structure as hormones the body produces, including estrogen and progesterone. The label describes a hormone’s structure, not how it is made or whether it is safer or more effective than another treatment. The Menopause Society explains that bioidentical hormones are available in FDA-approved products as well as compounded preparations.
The terms are not interchangeable: some FDA-approved medicines contain bioidentical hormones, while custom-compounded products are prepared by pharmacies for an individual prescription. A plant-derived starting ingredient does not determine whether the finished medicine is compounded or approved. Nor does customization itself show that a preparation works better or carries fewer risks.
Approved options include estradiol in forms such as pills, patches, gels, sprays, vaginal creams, tablets, and rings, as well as oral micronized progesterone. Approval applies to particular products and uses, not every product containing the same hormone. A clinician can help match an option to symptoms, medical history, and preferences. For more on the distinction between body-identical hormones and custom preparations, see the difference between bioidentical and compounded hormones.
Compounded products are not FDA-approved, and their quality and strength are not assessed in the same way as approved medicines. The American College of Obstetricians and Gynecologists’ guidance on compounded bioidentical hormone therapy advises discussing those limitations when considering treatment. At harmony.care, women’s health care is grounded in personalized, evidence-based assessment, so treatment discussions can take a patient’s symptoms and health history into account rather than relying on a label alone.
What Compounding Changes
Compounded hormones are prepared by a pharmacy from a clinician’s prescription. A custom dose or form may be considered when an approved product cannot meet a specific medical need, such as an allergy to an ingredient. That practical purpose is different from routine customization based on a promise of better results.
FDA-approved products undergo review for safety and effectiveness and are manufactured to meet standards for consistent quality. Compounded products are not FDA-approved and are not reviewed in the same way. Their dose, potency, purity, absorption, and quality may vary; contamination is also a concern, and pharmacies are not required to report adverse events to the FDA. The American College of Obstetricians and Gynecologists’ guidance recommends against routinely prescribing compounded bioidentical therapy when FDA-approved options are available.
The distinction is not simply “bioidentical” versus conventional: some approved products contain hormones chemically identical to those made by the body. Evidence does not establish that compounded products are safer, more effective, or better personalized. When a custom preparation is being considered, a clinician can explain why an approved option may not fit, what uncertainties remain, and how treatment response and safety will be followed. At harmony.care, hormone decisions are considered in the context of a person’s symptoms and health history, rather than relying on the product label alone.
Weighing Benefits and Risks
For bothersome hot flashes and night sweats, menopausal hormone therapy (MHT) is the most effective treatment. It can also ease vaginal symptoms, and systemic therapy may help protect bone health in appropriate circumstances. These benefits should be weighed against risks that vary with the specific hormones and dose, how they are taken, treatment duration, age, and personal medical history. The Menopause Society’s hormone therapy guidance describes this individualized balance.
Systemic therapy may increase the risk of blood clots and stroke. Breast cancer risk may also rise over time with certain combined estrogen-progestogen regimens, but no single risk estimate applies to everyone. For someone with a uterus, systemic estrogen is generally paired with a progestogen to protect the uterine lining. Using systemic estrogen without that protection can increase endometrial cancer risk.
Low-dose vaginal estrogen is used for local symptoms, such as vaginal dryness, and has much less absorption into the bloodstream than systemic therapy. It is not interchangeable with systemic treatment, and suitability still depends on individual circumstances. A clinician can help compare options and review risks in light of symptoms, preferences, and medical history. Patients can also explore how hormone therapy fits within an integrative care plan.
“Bioidentical” describes a hormone’s chemical structure, not a safety advantage. Some FDA-approved therapies contain bioidentical hormones; custom-compounded products are not reviewed by the FDA for safety and effectiveness in the same way and may vary in strength or quality. The American College of Obstetricians and Gynecologists’ guidance on compounded therapy recommends discussing FDA-approved options when available. A personalized care discussion can focus on the actual product, route, and health history rather than the label alone.
Cancer Risk Depends on the Regimen
Menopausal hormone therapy (MHT) does not carry the same cancer risks for everyone. The balance depends on the hormones used, how long treatment continues, and a person’s medical history and other risk factors. The American College of Obstetricians and Gynecologists’ guidance on hormone therapy describes these risks as part of an individualized treatment discussion.
For someone with a uterus, systemic estrogen is generally paired with a progestogen to protect the uterine lining from overgrowth that can lead to endometrial cancer. Combined estrogen-progestogen therapy has also been associated with increased breast cancer risk, especially with longer use. Estrogen-only therapy has a different risk profile and is generally considered for people who have had a hysterectomy.
A personal history of breast cancer can affect whether systemic MHT is appropriate. Discuss your treatment choices with your clinician and, when relevant, your oncology team, to make a decision that fits your health history and preferences.
Personalize Eligibility and Duration
Deciding whether to use menopausal hormone therapy (MHT) starts with the person, not a standard age cutoff or one-size-fits-all regimen. A clinician considers symptoms, health history, preferences, age, and time since menopause. For otherwise healthy people with bothersome hot flashes or night sweats, the benefit-risk balance is often more favorable before age 60 or within 10 years of menopause, when no contraindications are present, according to The Menopause Society’s hormone therapy guidance.
Systemic MHT may be unsuitable, or may call for specialist assessment, with a history of estrogen-sensitive cancer, unexplained vaginal bleeding, severe active liver disease, coronary heart disease, stroke, heart attack, or blood clots. A personal or inherited clotting risk also deserves careful review. These factors do not have identical implications for every treatment. Systemic therapy and low-dose vaginal estrogen are not interchangeable, so the symptom being treated and the route matter.
At harmony.care, an integrative women’s health practice, treatment discussions can account for symptoms, medical history, and individual goals rather than relying on a hormone label alone. If a person has a uterus, systemic estrogen is generally paired with a progestogen to protect the uterine lining; after hysterectomy, estrogen alone may be appropriate. Low-dose vaginal estrogen may be considered when symptoms are limited to vaginal or urinary concerns.
There is no universal maximum duration or age at which everyone must stop MHT. If treatment continues to ease symptoms and its benefits still outweigh its risks, a clinician can review whether to continue, adjust the dose, or try stopping. Regular reassessment matters because health conditions, symptoms, and preferences can change. Discuss any decision to start, change, or stop treatment with a clinician rather than making the adjustment on your own.
Side Effects and Questions to Ask
Side effects vary with the hormone, dose, delivery method, and a person’s health history. They may include breast tenderness, bloating, headaches, nausea, or irregular bleeding. A Cleveland Clinic overview of bioidentical hormones explains that some effects may ease, while persistent or troublesome symptoms may call for a treatment adjustment.
Compounded products can have less predictable potency and absorption than FDA-approved medicines, and pellets release hormones over time, making a dose difficult to adjust or remove if problems arise. For context on possible effects and monitoring, see this guide to hormone therapy side effects and safety questions.
Contact a healthcare professional about persistent, severe, or unexpected symptoms, especially new or unexplained vaginal bleeding. Salivary hormone testing is not recommended to prescribe or dose compounded menopausal hormone therapy because the evidence is limited and saliva levels do not reliably correspond to symptoms, as ACOG’s clinical consensus explains.
A shared decision-making conversation can clarify what to expect and how to follow up. Ask whether the proposed medicine is FDA-approved or compounded, which symptom it is meant to treat, what alternatives and health-history risks apply, and how you will assess whether it is helping.
Make the Choice Together
The word “bioidentical” describes a hormone’s structure, not the quality, oversight, evidence, or risks of the product it comes in. FDA-approved options and custom-compounded preparations are not interchangeable, and neither the label “natural” nor a personalized formula proves a treatment is safer or works better, as ACOG’s guidance on compounded hormone therapy explains.
Bring your symptoms, medical history, preferences, and questions to a qualified healthcare professional. At harmony.care, women’s health and hormone concerns are approached through naturopathic and functional medicine; use that conversation to weigh evidence and individual circumstances, not marketing promises, and agree on a plan together.
